Company Coretag, Inc.

Coretag, Inc. is focused on the development of cancer imaging and targeted radiotherapy, based on its Necrosis Targeting Platform Technology (NTPT). The Company developed NTPT as a result of the discovery of a group of cyanine dyes which have selective targeting properties for intracellular proteins. These proteins become available for binding only when the cell membrane loses its integrity, which occurs once a cell has become necrotic. The Company has developed a portfolio of products that address high unmet needs in oncology. The Company develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis. It also develops targeted diagnostics with 89Zr (zirconium) and 111In (indium) for detecting and quantifying necrotic tissue in the human body.